{
    "clinical_study": {
        "@rank": "135982", 
        "acronym": "BRAVO 2/3", 
        "arm_group": [
            {
                "arm_group_label": "Bivalirudin during Trans-Aortic Valve Replacement", 
                "arm_group_type": "Experimental", 
                "description": "Bivalirudin will be administered as a bolus and infusion. It is recommended that the bolus (0.75 mg/kg) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access.  Systemic IV administration of the bolus dose is also acceptable. The bivalirudin intravenous infusion is initiated immediately after the bolus administration"
            }, 
            {
                "arm_group_label": "Unfractionated heparin during Trans-Aortic Valve Replacement", 
                "arm_group_type": "Active Comparator", 
                "description": "The dose of UFH should adhere to the standard institutional practice.  An ACT target \u2265 250 seconds is recommended"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an international, multicenter, open-label, randomized controlled trial.  All\n      patients undergoing transfemoral TAVR at the participating centers will be eligible.  All\n      sites will initiate enrolment with 2 feasibility roll-in bivalirudin treated patients and\n      thereafter patients will be randomly assigned to either standard dosing of bivalirudin or\n      UFH as control. The 2 roll-in cases per site will constitute the feasibility cohort that\n      will be followed and analyzed separately.  Patients will undergo TAVR according to current\n      standard of care practices at the treating centers. Use of antiplatelet agents pre, during,\n      and post procedure, and possibly oral anticoagulants post procedure, will be according to\n      the sites' standard practice. ALL available data will be collected in the eCRF prospectively"
        }, 
        "brief_title": "International, Multi-center, Open-label, Randomized Controlled Trial in Patients Undergoing TAVR to Determine the Treatment Effect (Both Safety and Efficacy) of Using Bivalirudin Instead of UFH.", 
        "condition": [
            "Severe Aortic Stenosis", 
            "Aortic Valve Insufficiency", 
            "Transcatheter Aortic Valve Replacement", 
            "Aortic Valve Replacement"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aortic Valve Insufficiency", 
                "Aortic Valve Stenosis", 
                "Constriction, Pathologic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be an international, multi-center, open-label, randomized controlled trial\n      in patients undergoing TAVR. Following the conclusion of the roll-in phase of 2 patients per\n      site, who will comprise the feasibility cohort of approximately 70 patients, 550 patients\n      will be randomized to bivalirudin or UFH at approximately 35 centers. Informed consent will\n      be obtained from patients meeting the inclusion criteria before the initiation of any\n      study-specific procedures."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years of age\n\n          -  High risk (Euroscore \u226518, or considered inoperable) for surgical aortic valve\n             replacement\n\n          -  Undergoing TAVR via transfemoral arterial access\n\n          -  Provide written informed consent before initiation of any study related procedures\n\n        Exclusion Criteria:\n\n          -  Any known contra\u2010indication to the use of bivalirudin (except presence of severe\n             renal impairment [GFR<30 ml/min] since these patients will be included in the trial\n             or UFH\n\n          -  Refusal to receive blood transfusion\n\n          -  Mechanical valve (any location) or mitral bioprosthetic valve\n\n          -  Extensive calcification of the common femoral artery, or minimal luminal diameter<\n             6.5 mm\n\n          -  Use of elective surgical cut-down for transfemoral access\n\n          -  Concurrent performance of percutaneous coronary intervention with TAVR\n\n          -  International normalized ratio (INR) \u2265 2 on the day of TAVR procedure, or known\n             history of bleeding diathesis\n\n          -  History of hemorrhagic stroke, intracranial hemorrhage, intracerebral mass or\n             aneurysm, or arteriovenous malformation\n\n          -  Severe left ventricular dysfunction (left ventricular ejection fraction<15%)\n\n          -  Severe aortic regurgitation or mitral regurgitation (4+)\n\n          -  Hemodynamic instability (e.g. requiring inotropic or IABP support) within 2 hours of\n             the procedure\n\n          -  Dialysis dependent\n\n          -  Administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, or warfarin in the\n             3 days prior to the procedure\n\n          -  Acute myocardial infarction, major surgery or any therapeutic cardiac procedure\n             (other than balloon aortic valvuloplasty) within 30 days\n\n          -  Percutaneous coronary intervention within 30 days\n\n          -  Upper gastrointestinal or genitourinary bleed within 30 days\n\n          -  Stroke or transient ischemic attack within 30 days\n\n          -  Any surgery or biopsy within 2 weeks\n\n          -  Administration of:\n\n               -  UFH within 30 minutes of the procedure\n\n               -  Enoxaparin within 8 hours of the procedure\n\n               -  Fondaparinux or other LMWHs within 24 hours of the procedure\n\n               -  Dabigatran, rivaroxaban or other oral anti-Xa or antithrombin agent within 48\n                  hours of the procedure\n\n               -  Thrombolytics, GPI, or warfarin within 72 hours of the procedure\n\n          -  Absolute contraindications or allergy that cannot be pre-medicated to iodinated\n             contrast\n\n          -  Contraindications or allergy to aspirin or clopidogrel\n\n          -  Known or suspected pregnant women, or nursing mothers. Women of child\u2010bearing\n             potential will be asked if they are pregnant and will be tested for pregnancy\n\n          -  Previous enrolment in this study\n\n          -  Treatment with other investigational drugs or devices within the 30 days preceding\n             enrollment or planned use of other investigational drugs or devices before the\n             primary endpoint of this study has been reached Patients excluded for any of the\n             above reasons may be re-screened for participation at any time if the exclusion\n             characteristic has changed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "620", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651780", 
            "org_study_id": "Protocol No. TMC-BIV-11-02", 
            "secondary_id": "2012\u2010000632\u201026"
        }, 
        "intervention": {
            "arm_group_label": [
                "Bivalirudin during Trans-Aortic Valve Replacement", 
                "Unfractionated heparin during Trans-Aortic Valve Replacement"
            ], 
            "description": "transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach", 
            "intervention_name": "Trans-Aortic Valve Replacement", 
            "intervention_type": "Procedure", 
            "other_name": "TAVR"
        }, 
        "intervention_browse": {
            "mesh_term": "Bivalirudin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transcatheter aortic valve replacement", 
            "aortic valve replacement", 
            "aortic valve insufficiency", 
            "severe aortic stenosis"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "zip": "V6Z1Y6"
                    }, 
                    "name": "St. Paul\u00b4s Hospital Providence Health Care"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "state": "Cedex9", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Toulouse"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "hengstenberg@dhm.mhn.de", 
                    "last_name": "Christian Hengstenberg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "80636"
                    }, 
                    "name": "Deutsches Herzzentrum M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Christian Hengstenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "colombo.antonio@hsr.it", 
                    "last_name": "Antonio Colombo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "Ospedale San Raffaele U.O. Cardiologia Interventistica"
                }, 
                "investigator": {
                    "last_name": "Antonio Colombo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.ten.berg@antoniusziekenhuis.nl", 
                    "last_name": "Jur ten Berg, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3435"
                    }, 
                    "name": "St. Antonius Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "Jur ten Berg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stephan.windecker@insel.ch", 
                    "last_name": "Stephan Windecker, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "3010"
                    }, 
                    "name": "Universit\u00e4tsklinik Bern"
                }, 
                "investigator": {
                    "last_name": "Stephan Windecker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Hildick-Smith, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brighton", 
                        "country": "United Kingdom", 
                        "state": "East Sussex", 
                        "zip": "BN2 5BE"
                    }, 
                    "name": "The Royal Sussex County Hospital"
                }, 
                "investigator": {
                    "last_name": "David Hildick-Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)", 
        "overall_contact": {
            "email": "grubeE@aol.com", 
            "last_name": "Eberhardt Grube, MD"
        }, 
        "overall_contact_backup": {
            "email": "t.lefevre@angio-icps.com", 
            "last_name": "Thierry Lefevre, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "H\u00f4pital Priv\u00e9 Jacques Cartier", 
                "last_name": "Thierry Lefevre, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Medicines Company", 
                "last_name": "Prodromos Anthopoulos, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum Bonn", 
                "last_name": "Eberhardt Grube, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ethics Commission", 
                "Italy: Ethics Committee", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Netherlands:  Independent Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Switzerland: Ethikkommission", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary end point will be major bleeding defined as Bleeding Academic Research Consortium (BARC) type \u22653b at 48 hours or hospital discharge whichever occurs first.", 
            "measure": "Major Bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "48h post or discharge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary endpoints of this trial are: (1) Major bleeding according to additional scales (VARC, TIMI, GUSTO, ACUITY/HORIZONS); (2) Bleeding BARC \u22653; moderate bleeding BARC = 3a; minor bleeding (BARC type 1 and 2 and TIMI minor); (3) major adverse cardiac events (MACE) including death, non-fatal MI, and stroke; (4) the rates of the individual components of MACE; (5) transient ischemic attack; (6) acute kidney injury; (7) VARC major vascular complications; (8) acquired thrombocytopenia; (9) rate of new post-procedural atrial fibrillation/flutter; and (10) economic analysis of using bivalirudin in TAVR.", 
            "measure": "Bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "48 hours post-procedure"
        }, 
        "source": "The Medicines Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Medicines Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}